TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04490226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting, inactive
Description: 36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later.
Study: NCT03038399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.25 mg/day/day
Description: Oral administration of 0.25 mg/kg/day daily for 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.75 mg/day/day
Description: Oral administration of 0.75 mg/kg/day daily for 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 2.0 mg/day/day
Description: Oral administration of 2.0 mg/kg/day daily for 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 6.0 mg/day/day
Description: Oral administration of 6.0 mg/kg/day daily for 24 months.
Study: NCT00143936

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low- Carbohydrate -Atkins Diet
Description: Low Carbohydrate Diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Diet
Description: Maintain a low calorie diet
Study: NCT04107129

Intervention type: PROCEDURE
Intervention: Endometrial Biopsy
Description: An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers

Intervention type: PROCEDURE
Intervention: Endometrial Biopsy
Description: An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers

Intervention type: PROCEDURE
Intervention: Endometrial Biopsy
Description: An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers

Intervention type: OTHER
Intervention: Euploid embryo transfer
Description: Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.

Intervention type: OTHER
Intervention: Euploid embryo transfer
Description: Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.

Intervention type: OTHER
Intervention: Euploid embryo transfer
Description: Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.
Study: NCT04328870

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin and spinal anesthesia
Description: start oxytocin 10 IU/200 ml saline at the insertion of the spinal anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthsia
Description: General anesthesia alone.
Study: NCT03490409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thigh compression stocking
Description: Thigh compression stocking
Study: NCT01533649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Andrews/Reiter approach to epilepsy
Description: The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation/Meditation
Description: Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
Study: NCT04224194

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Adalimumab
Description: Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.
Study: NCT01104428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziying granules
Description: granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
Study: NCT03370107

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS
Description: Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
Study: NCT03998709

Intervention type: DRUG
Group type: OTHER
Intervention: Somatostatin
Description: Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study

Intervention type: DRUG
Group type: OTHER
Intervention: Somatostatin
Description: Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study

Intervention type: OTHER
Group type: OTHER
Intervention: Dextrose
Description: intravenous glucose will be used to raise fasting glucose in people with NFG / NGT

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: insulin will be used to lower fasting FFA and glucose in people with IFG / IGT

Intervention type: OTHER
Group type: OTHER
Intervention: Intralipid
Description: intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
Study: NCT02008643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: filling questionnary to quality of life
Description: filling questionnary to quality of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: filling questionnary to quality of life
Description: filling questionnary to quality of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: filling questionnary to quality of life
Description: filling questionnary to quality of life
Study: NCT03650114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: subcutaneous injection of 20 mg ofatumumab every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) containing vaccine (Td, Tdap)
Description: 0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13-PCV)
Description: 0.5mL Vial/Syringe

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Description: 0.5mL Vial/Syringe

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Quadrivalent influenza vaccine
Description: Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin (KLH) neo-antigen
Description: 1mg Vial
Study: NCT03493425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00787150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 5 mg tablet BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 2.5 mg tablet BID for 12 weeks
Study: NCT03493425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study: NCT00787150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin sodium
Description: At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
Study: NCT03493425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study: NCT03571620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q301 Cream
Description: 1.0% or 1.4% Q301 Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q301 Cream
Description: 1.0% or 1.4% Q301 Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Control
Study: NCT01601054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tantalum cage from Zimmer
Description: A tantalum cage will be inserted through a left sided retroperitoneal approach

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tantalum cage from Zimmer
Description: A tantalum cage will be inserted through a left sided retroperitoneal approach
Study: NCT03194152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut
Description: Dietary Supplement: Peanut

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Dietary Supplement: High carbohydrate snacks
Study: NCT02524860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal-Fusion Bx
Description: The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
Study: NCT03591679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 20 units by slow intravenous drip injection
Study: NCT04695665

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical pain
Description: Exercise program for cervical spine according to McGill's approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic pain
Description: Exercise program for thoracic spine according to McGill's approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar pain
Description: Exercise program for lumbar spine according to McGill's approach.
Study: NCT00867139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCAD
Description: TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zanamivir or Oseltamivir
Description: Zanamivir or Oseltamivir

Intervention type: OTHER
Group type: OTHER
Intervention: Open label treatment with TCAD
Description: TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
Study: NCT03591679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 units by slow intravenous drip injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral uterine artery ligation
Description: • The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
Study: NCT01203397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G
Description: APLIED 4 TIMES/DAY AT LESION

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G
Description: APLIED 4 TIMES/DAY AT LESION
Study: NCT02824679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butylbromide
Description: 20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butylbromide
Description: 20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
Study: NCT01469013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Study: NCT02902432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
Study: NCT01741974

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Karinat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Karinat 500 mg tablet
Study: NCT04107129

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Estradiol and Progesterone levels in the blood will be checked

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Estradiol and Progesterone levels in the blood will be checked

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Estradiol and Progesterone levels in the blood will be checked
Study: NCT06278025

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment
Description: DCF Muscle Strength Evaluation~DCF muscle strength was determined using the 5-step Craniocervical Flexion Test (CCFT) performed with a Chattanooga Stabilizer ™ Pressure Biofeedback Unit which was developed by Jull et al. \[33, 34\]. The CCFT is based on the craniocervical flexion movement, which is provided by DCF muscle contraction. The CCFT includes 5 pressure increments starting with 20mmHg.Activation score ranges from 0 to 10. The performance index is determined by both the highest pressure level and the number of repetitions.~Evaluation of the DCF Endurance The DCF endurance test, which is a valid and reliable method, was used to measure DCF muscle endurance \[36\]. Conducted in supine, endurance is measured by calculating the time (in seconds) an individual can raise their head at minimal flexion angle.

Intervention type: DIAGNOSTIC_TEST
Intervention: assessment
Description: DCF Muscle Strength Evaluation~DCF muscle strength was determined using the 5-step Craniocervical Flexion Test (CCFT) performed with a Chattanooga Stabilizer ™ Pressure Biofeedback Unit which was developed by Jull et al. \[33, 34\]. The CCFT is based on the craniocervical flexion movement, which is provided by DCF muscle contraction. The CCFT includes 5 pressure increments starting with 20mmHg.Activation score ranges from 0 to 10. The performance index is determined by both the highest pressure level and the number of repetitions.~Evaluation of the DCF Endurance The DCF endurance test, which is a valid and reliable method, was used to measure DCF muscle endurance \[36\]. Conducted in supine, endurance is measured by calculating the time (in seconds) an individual can raise their head at minimal flexion angle.
Study: NCT01137266

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS
Study: NCT01191619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McIvor retractor
Description: The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
Study: NCT05038072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suprachoroidal injection of Triamcinolone Acetonide.
Description: 4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
Study: NCT03552913

Intervention type: PROCEDURE
Intervention: One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
Description: One year before awareness-raising phase in favour of Enhanced Recovery After Surgery

Intervention type: PROCEDURE
Intervention: One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
Description: One year after awareness-raising phase in favour of Enhanced Recovery After Surgery

Intervention type: PROCEDURE
Intervention: No specific program toward improving practices
Description: No specific program toward improving practices

Intervention type: PROCEDURE
Intervention: No specific program toward improving practices
Description: No specific program toward improving practices
Study: NCT02772653

Intervention type: OTHER
Intervention: Blood Lactate
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission

Intervention type: OTHER
Intervention: Blood Base Excess
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission
Study: NCT00588731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Active Cannabidiol daily over 6 weeks
Study: NCT02772653

Intervention type: OTHER
Intervention: Blood B-type Natriuretic Peptide
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission
Study: NCT00588731

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04197128

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resorbable Collagen membrane with bone graft for augmentation
Description: Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision. Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, bovine bone graft will be place with overlying resorbable collagen membrane. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted Vicryl 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)
Study: NCT01469013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Study: NCT02772653

Intervention type: OTHER
Intervention: Blood Thromboelastometry (ROTEM)
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission

Intervention type: OTHER
Intervention: Near-infrared spectroscopy
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission

Intervention type: OTHER
Intervention: Sublingual videomicroscopy
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission
Study: NCT00750750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate nasal spray (MFNS)
Description: Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
Study: NCT04197128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ribose cross linked collagen matrix for augmentation
Description: Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision.~Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, ribose cross linked collagen matrix will be cut and adapted to the buccal wall and ridge around the buccal aspect of healing abutment. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany).
Study: NCT00750750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFNS
Description: Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
Study: NCT00624312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procrit
Description: 10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo